3 in 4 surveyed patients show strong interest in replacing medications with both approved and experimental treatments.

Over 131 million people in the US — roughly 66% of Americans — take prescription drugs regularly. That’s more than the number of people who watched the Super Bowl this year. And yet, 1 in 3 surveyed patients who take prescription medications said that they were unsatisfied with at least one of their current drugs. […]
RWE Won’t Replace Clinical Trials – But It Can Improve Them
Although real world evidence (RWE) is gaining steam in the healthcare industry, it doesn’t pose a threat to traditional clinical trials. Here’s what sponsors and CRO’s need to know:
How Sponsors and CROs Can Make Clinical Trial Data More Accessible
Sponsors and CROs can improve patient centricity and boost clinical trial recruitment by developing better data-sharing practices.
Using Data to Boost Patient Enrollment and Improve Clinical Trial Design
Data analytics can help make clinical trials more efficient, cost-effective, and patient-centric.
It’s Time for Clearer Data Standards in Clinical Trials
The way clinical trials use patient data is rapidly changing, revealing a need for increased privacy regulations and standardization across the industry.
Nearly a Third of Healthcare Organizations Still Aren’t Compliant with GDPR
A recent study shows that many healthcare providers do not meet EU standards for data security, but the industry is working to increase protection for patients.
Revolutionizing Clinical Trials through Real-Time Data Capture and Analytics
In the digital age, legacy clinical trial data platforms aren’t enough. Here’s what real-time data can bring to the table.
How Pragmatic Clinical Trials Generate Better Data and Outcomes
Pragmatic trials offer real-world data on the efficacy of a treatment – and an opportunity to take advantage of new medical technology.
Will Amazon Be the Next Big Disruptive Force in Clinical Trials?
From grocery stores to natural language processing, Amazon’s ambitions seem to know no bounds – will clinical trials be its next target?